About James Wetherill

This author has not yet filled in any details.
So far James Wetherill has created 282 blog entries.

CEO Update: Going for the Gold in All We Do

2021-06-24T14:22:11-04:00June 24th, 2021|

Here’s another reason to be proud of the hard-working Pulmonary Hypertension Association staff: We recently won two EXCEL awards for outstanding communications and marketing efforts. Our 2020 Pulmonary Hypertension Awareness Month: disCOVER PH campaign, received a gold award for advocacy/awareness campaigns. We also received a bronze award for our 2020 COVID-19 pandemic response.

Register for PHPN Symposium by July 7 for Early Discount

2021-06-24T13:31:43-04:00June 24th, 2021|

Register for this year’s PH Professional Network (PHPN) Symposium by July 7 to save up to $300 on registration. PHPN Symposium, “PHiguring Out the Puzzle: Pieces to Innovative, Patient-Centered Care,” will take place online Sept. 30 through Oct. 3. Join other allied health professionals to network, learn about PH research and care advancements, and earn continuing education credit.

Missed Our COVID-19 Task Force Q&A? Watch the Recording

2021-06-24T13:30:27-04:00June 24th, 2021|

Members of the Pulmonary Hypertension Association (PHA) COVID-19 task force answered questions about pandemic issues in a May 27 webinar, including vaccine myths. Cardiologist Mardi Gomberg, M.D., M.Sc., of the George Washington University School of Medicine and Health Sciences, explained how the vaccines work as part of the event.

Medtronic, United Therapeutics Halt ISR development

2021-06-24T13:25:49-04:00June 24th, 2021|

Medtronic and United Therapeutics have terminated development of the Implantable System for Remodulin (ISR). United Therapeutics will continue to support clinical study participants who use the ISR. United Therapeutics and Medtronic have committed to continue supporting patients currently on the ISR. They will evaluate the feasibility of making replacement pumps available for current ISR patients if and/or when necessary. Learn more.